Abivax Reports Q1 2025 Financial Results

Abivax SA, a clinical-stage biotechnology firm, announced its financial outcomes for the first quarter of 2025. The company, listed on Euronext Paris and Nasdaq, focuses on developing treatments for chronic inflammatory diseases. Operating loss grew to EUR 47.2M, a rise from EUR 44.7M the previous year, due to increased research and development expenses. R&D costs surged by EUR 3.6M, mainly driven by advancements in their Crohn’s Disease program.

The company managed to decrease sales and marketing expenses significantly, cutting them to EUR 0.9M from EUR 2.0M. Net financial loss reached EUR 5.2M, affected by interest expenses and foreign exchange losses. As of March 31, 2025, Abivax's cash position was EUR 103.6M, down from EUR 144.2M at the end of 2024, impacted by operating activities and debt repayments. Abivax projects its current finances will support operations into Q4 2025.